Trial Profile
A Phase 1/2a, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients With Non-Small Cell and Small Cell Lung Cancer - SCope-D1
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary)
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SCope-D1
- Sponsors AstraZeneca
- 26 Sep 2023 Status changed from active, no longer recruiting to completed.
- 01 Feb 2023 Planned End Date changed from 19 Jan 2024 to 15 Sep 2023.
- 01 Feb 2023 Planned primary completion date changed from 19 Jan 2024 to 15 Sep 2023.